Spire Wealth Management Increases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Spire Wealth Management raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1,342.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,429 shares of the biopharmaceutical company’s stock after acquiring an additional 13,429 shares during the period. Spire Wealth Management’s holdings in Catalyst Pharmaceuticals were worth $301,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after buying an additional 151,495 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Catalyst Pharmaceuticals by 4.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after buying an additional 50,804 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Catalyst Pharmaceuticals by 245.4% during the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Catalyst Pharmaceuticals by 146.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after acquiring an additional 217,956 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CPRX. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday. StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. HC Wainwright lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, Robert W. Baird initiated coverage on Catalyst Pharmaceuticals in a report on Tuesday. They set an “outperform” rating and a $28.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.25.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,500 shares of company stock worth $1,754,140. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 1.5 %

NASDAQ CPRX opened at $23.06 on Friday. The stock’s 50 day moving average is $22.07 and its two-hundred day moving average is $20.87. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.12 and a 1-year high of $24.64. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 2.25 and a beta of 0.80.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.